Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patien...
Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain
7 Dec 2020
FORTE trial: Impact of minimal residual disease on multiple myeloma patients
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy
7 Dec 2020
Evaluation of MRD negativity in patients with relapsed or refractory multiple my...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
7 Dec 2020
ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma
Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA
7 Dec 2020
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma
Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA
7 Dec 2020
Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in ne...
Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA
7 Dec 2020
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelph...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
7 Dec 2020
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
7 Dec 2020
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Trea...
Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands
7 Dec 2020
Predictive factors for overall survival in chronic myeloid leukaemia patients: a...
Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy
6 Dec 2020
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potent...
Prof David Teachey - The University of Pennsylvania, Rutledge, USA
6 Dec 2020
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukae...
Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA
5 Dec 2020
